Lupin gains USFDA approval for generic glycerol phenylbutyrate, entering U.S. rare disease market, boosting portfolio, revenues, and affordable treatment access.
Global pharmaceutical company Lupin Limited has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. This significant approval, announced on May 5, 2026, marks Lupin's entry into a specialized and high-value therapeutic area within the U.S. market.
The approved oral liquid is bioequivalent to Ravicti® Oral Liquid, 1.1 grams per mL, the reference listed drug (RLD) manufactured by Horizon Therapeutics U.S. Holding LLC. This bioequivalence ensures that Lupin's generic version will offer the same dosage, safety, strength, and efficacy as the branded drug.
The drug is specifically indicated for the chronic management of patients suffering from urea cycle disorders (UCDs). UCDs are a group of rare genetic conditions that impair the body's ability to process and remove ammonia from the bloodstream. Glycerol Phenylbutyrate Oral Liquid is prescribed for patients whose conditions cannot be adequately managed through dietary protein restriction and/or amino acid supplementation alone, making it a crucial treatment option for individuals with these complex metabolic disorders.
The economic impact of this approval is substantial for Lupin. This considerable market size presents a significant opportunity for Lupin's generic offering, allowing it to provide a more cost-effective alternative to patients and healthcare systems.
For Lupin, a global pharmaceutical leader headquartered in Mumbai, India, with operations in over 100 markets, this USFDA approval further strengthens its presence in the competitive U.S. generics market. The company has a strong focus on expanding its portfolio of specialized and complex generic drugs, and this approval aligns with that strategic objective. The U.S. business alone contributed 36% to Lupin's total revenues in FY25, highlighting the importance of such approvals for the company's financial growth and market position. By offering a generic version of a high-value drug for a critical unmet medical need, Lupin reinforces its commitment to improving patient outcomes and expanding access to quality healthcare worldwide.
